Regen BioPharma, Inc.
RGBP
$0.00
$0.000.00%
OTC PK
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | |
|---|---|---|---|---|---|
| Revenue | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| SG&A Expenses | 62.07% | 63.75% | 73.54% | 12.66% | 6.76% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 93.60% | 82.88% | 79.86% | -12.04% | -14.34% |
| Operating Income | -167.17% | -136.13% | -132.87% | 18.86% | 23.04% |
| Income Before Tax | -21.95% | 23.49% | -66.28% | -90.75% | -34.64% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -21.95% | 23.49% | -66.28% | -90.75% | -34.64% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -21.95% | 23.49% | -66.28% | -90.75% | -34.64% |
| EBIT | -167.17% | -136.13% | -132.87% | 18.86% | 23.04% |
| EBITDA | -- | -- | -- | -- | -- |
| EPS Basic | 86.16% | 83.34% | 81.21% | -87.08% | -91.67% |
| Normalized Basic EPS | 86.19% | 83.33% | 81.14% | -87.28% | -79.75% |
| EPS Diluted | 86.16% | 83.34% | 81.21% | -87.08% | -91.67% |
| Normalized Diluted EPS | 86.19% | 83.33% | 81.14% | -87.28% | -79.75% |
| Average Basic Shares Outstanding | 1,496.38% | 691.43% | 497.24% | 150.76% | 83.15% |
| Average Diluted Shares Outstanding | 1,496.38% | 691.43% | 497.24% | 150.76% | 83.15% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |